We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pluristem’s Proprietary PLX Cells Demonstrate Promising Potential in Treating Autoimmune Disorders
News

Pluristem’s Proprietary PLX Cells Demonstrate Promising Potential in Treating Autoimmune Disorders

Pluristem’s Proprietary PLX Cells Demonstrate Promising Potential in Treating Autoimmune Disorders
News

Pluristem’s Proprietary PLX Cells Demonstrate Promising Potential in Treating Autoimmune Disorders

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pluristem’s Proprietary PLX Cells Demonstrate Promising Potential in Treating Autoimmune Disorders"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pluristem Therapeutics, Inc. has announced that in vitro testing of its PLacenta eXpanded (PLX) cells demonstrated the potential to treat autoimmune disorders. This testing showed a significant reduction of TNF-a and interferon-? inflammatory cytokines that are known to be involved in the pathogenesis of autoimmune disorders.

Reducing TNF-a and interferon-? is considered a key factor in mitigating the symptoms of autoimmune disorders, such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Crohn’s Disease and Juvenile (Type 1) Diabetes.

“We are excited that our PLX cells demonstrate the potential to treat autoimmune disorders,” said Zami Aberman, Pluristem’s President and CEO.

“The strong anti-inflammatory results show that our PLX cells may have the capability to help millions of patients and represent an additional potential multi-billion dollar market for our PLX cells. These impressive results suggest that our 3D-expanded placental cells could become an allogeneic, non-controversial source for stem cell therapeutics in the future,” continued Aberman.

Advertisement